{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:55:43Z","timestamp":1780048543547,"version":"3.53.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/fjc.0b013e318074f934","type":"journal-article","created":{"date-parts":[[2007,8,13]],"date-time":"2007-08-13T07:04:00Z","timestamp":1186988640000},"page":"213-222","source":"Crossref","is-referenced-by-count":45,"title":["Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide"],"prefix":"10.1097","volume":"50","author":[{"given":"Susan E","family":"Shoaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L","family":"Bramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bricmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210208","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMoa010641","article-title":"Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure.","volume":"345","author":"Drazner","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-15-20210208","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","article-title":"Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.","volume":"41","author":"Nohria","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R3-15-20210208","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mhj.2000.110933","article-title":"Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure.","volume":"140","author":"Lucas","year":"2000","journal-title":"Am Heart J"},{"key":"R6-15-20210208","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/euhj.2001.2783","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure.","volume":"22","author":"Remme","year":"2001","journal-title":"Eur Heart J"},{"key":"R12-15-20210208","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.ph.58.030196.003155","article-title":"Pathophysiology of the aquaporin water channels.","volume":"58","author":"King","year":"1996","journal-title":"Annual Rev Physiol"},{"key":"R13-15-20210208","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-15-20210208","first-page":"288","article-title":"Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther.","volume":"292","author":"Hirano","year":"2000","journal-title":""},{"issue":"Suppl 3","key":"R16-15-20210208","first-page":"33","article-title":"Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects.","volume":"41","author":"Reyes","year":"1991","journal-title":"Drugs"},{"key":"R17-15-20210208","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00877955","article-title":"Clinicopharmacological reappraisal of the potency of diuretics.","volume":"7","author":"Reyes","year":"1993","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"R21-15-20210208","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2362.1982.tb01000.x","article-title":"The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects.","volume":"12","author":"Andreasen","year":"1982","journal-title":"Eur J Clin Invest"},{"key":"R23-15-20210208","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl A","key":"R24-15-20210208","doi-asserted-by":"crossref","first-page":"156A","DOI":"10.1016\/S0735-1097(02)80688-X","article-title":"Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract].","volume":"39","author":"Udelson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R25-15-20210208","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/978-1-4615-4871-3_55","article-title":"VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.","volume":"449","author":"Chan","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"R26-15-20210208","first-page":"153","article-title":"Renal excretory actions of diuretics in man: correction of various current errors and redefinition of basic concepts.","volume":"6","author":"Leary","year":"1988","journal-title":"Progress in Pharmacology"},{"key":"R27-15-20210208","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/00365510510013659","article-title":"Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans.","volume":"65","author":"Starklint","year":"2005","journal-title":"Scand J Clin Lab Invest"},{"key":"R28-15-20210208","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated Heart Failure: Clinical and neuroendocrine effects of introducing diuretics.","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"R29-15-20210208","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1515\/CCLM.2004.108","article-title":"Cardiac natriuretic hormones, neurohormones, thyroid hormones and cytokines in normal subjects and patients with heart failure.","volume":"42","author":"Emdin","year":"2004","journal-title":"Clin Chem Lab Med"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00005344-200708000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T09:07:50Z","timestamp":1737364070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-200708000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e318074f934","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}